Fennec Pharmaceuticals Inc. (FRX.TO)
| Previous Close | 7.40 |
| Open | 7.52 |
| Bid | 7.36 x 0 |
| Ask | 7.46 x 0 |
| Day's Range | 7.40 - 7.52 |
| 52 Week Range | 4.95 - 13.25 |
| Volume | |
| Avg. Volume | 301 |
| Market Cap | 192.692M |
| Beta (5Y Monthly) | -0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.81 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM
- Zacks
Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- GlobeNewswire
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicit
